ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

Post-LOE

ipratropium bromide and albuterol sulfate

Nephron Pharmaceuticals

ANDAINHALATIONSOLUTION

Approved

Jul 2020

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE (ipratropium bromide and albuterol sulfate) by Nephron Pharmaceuticals is clinical pharmacology ipratropium bromide and albuterol sulfate inhalation solution is a combination of the β 2 -adrenergic bronchodilator, albuterol sulfate, and the anticholinergic bronchodilator, ipratropium bromide. Approved for bronchospasm associated with copd in patients requiring more than one bronchodilator, copd. First approved in 2020.

Drug data last refreshed 19h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Ipratropium bromide and albuterol sulfate inhalation solution is a combination of the β 2 -adrenergic bronchodilator, albuterol sulfate, and the anticholinergic bronchodilator, ipratropium bromide. Albuterol Sulfate Mechanism of Action The prime action of β-adrenergic drugs is…

Worked on ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE at Nephron Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

Mechanism of Action

Indications (2)